Praxis Precision Medicines

PRAX

Market cap $4.48B

Praxis Precision Medicines, Inc. is upgraded to a Strong Buy, driven by pipeline progress and positive phase 3 data for Ulixacaltamide in Essential Tremor. PRAX's Ulixacaltamide achieved primary endpoints in two phase 3 studies, positioning it as the first potential FDA-approved therapy for Essential Tremor, targeting a large unmet market. Upcoming PRAX catalysts include a pre-NDA meeting with the FDA in Q4 2025 and a potential NDA filing for Ulixacaltamide in 2026, alongside advancing late-stage trials for Vormatrigine and Relutrigine.

Praxis Precision Medicines, Inc. ( PRAX ) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies November 24, 2025 1:00 PM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Douglas Tsao - H.C. Wainwright & Co, LLC, Research Division Chuck McCullogh Presentation Douglas Tsao H.C.

Praxis Precision Medicines, Inc. ( PRAX ) Jefferies London Healthcare Conference 2025 November 18, 2025 8:30 AM EST Company Participants Marcio Souza - President, CEO & Director Conference Call Participants Lin Tsai - Jefferies LLC, Research Division Presentation Lin Tsai Jefferies LLC, Research Division All right. We're going to get started with our next session.

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on Deep Dive into Praxis' Ulixacaltamide Data with statistician Prof. Chuck McCullogh, University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza, Praxis' CEO.

A short seller is challenging Praxis Precision Medicines Inc. (NASDAQ: PRAX) after the company claimed success from its Phase 3 trial of ulixacaltamide.

Futures are trading higher this morning, as all the major indices once again closed lower on Tuesday, marking the fourth straight day of losses.

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on November 3, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 6,876 shares of its common stock to six new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock unit awards were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).

The volatile sector is seeing greater stability, and these four stocks can profit.

Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Shares of Praxis Precision Medicine shot 251% higher in a little over a week during the month of October. Praxis Precision Medicine announced successful results from a phase 3 trial with its lead candidate.